GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Non Operating Income
Switch to:

Biogen (MEX:BIIB) Non Operating Income

: MXN19,886 Mil (TTM As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Biogen's non-recurring items for the three months ended in Mar. 2023 was MXN-1,756 Mil. Its non-recurring items for the trailing twelve months (TTM) ended in Mar. 2023 was MXN19,886 Mil.

As of today (2023-05-30), Biogen's share price is MXN5300.00. Biogen's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was MXN425.37. Therefore, Biogen's PE Ratio without NRI ratio for today is 12.46.


Biogen Non Operating Income Historical Data

The historical data trend for Biogen's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Non Operating Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -257.22 2,972.34 15,549.58 -16,825.58 16,517.01

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Non Operating Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,601.43 8,363.05 11,714.98 1,563.58 -1,755.64

Biogen Non Operating Income Calculation

Non-Recurring Items are the incomes received or expenses incurred by the business that are not from regular operations. Examples of NRI include gains (losses) from plant shutdown, lease-breaking fees, lawsuit, write-offs, write-downs, restructuring costs or sales of an investment, discontinued operations etc.

NRI can impact a company's reported income drastically.

Non Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN19,886 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GuruFocus lists a PE Ratio without NRI, which is the price/earnings before NRI. We believe it more accurately reflects the valuation of the company.

Biogen's PE Ratio without NRI Ratio for today is calculated as

PE Ratio without NRI=Share Price/EPS without NRI
=5300.00/425.373
=12.46

Biogen's Share Price of today is MXN5300.00.
Biogen's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN425.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Non Operating Income Related Terms

Thank you for viewing the detailed overview of Biogen's Non Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines

Other Sources